A Look At SSY Group’s Valuation After 2025 Profit Guidance Signals A Sharp Earnings Drop

Simply Wall St.02-16

SSY Group (SEHK:2005) has issued preliminary 2025 earnings guidance, telling investors to expect a 45% to 60% reduction in profit attributable to equity shareholders compared with the HK$1,061,150,000...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611483678?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-02-16 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611483678","market":"nz","top_or_hot":-1,"title":"A Look At SSY Group’s Valuation After 2025 Profit Guidance Signals A Sharp Earnings Drop","media":"Simply Wall St.","content":"<div>\n<p>SSY Group (SEHK:2005) has issued preliminary 2025 earnings guidance, telling investors to expect a 45% to 60% reduction in profit attributable to equity shareholders compared with the HK$1,061,150,000...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/a-look-at-ssy-groups-valuation-after-2025-profit-guidance-si\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At SSY Group’s Valuation After 2025 Profit Guidance Signals A Sharp Earnings Drop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At SSY Group’s Valuation After 2025 Profit Guidance Signals A Sharp Earnings Drop\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-16 20:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/a-look-at-ssy-groups-valuation-after-2025-profit-guidance-si><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SSY Group (SEHK:2005) has issued preliminary 2025 earnings guidance, telling investors to expect a 45% to 60% reduction in profit attributable to equity shareholders compared with the HK$1,061,150,000...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/a-look-at-ssy-groups-valuation-after-2025-profit-guidance-si\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SSY","symbol_name":"Sunlink Health Systems Inc","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/a-look-at-ssy-groups-valuation-after-2025-profit-guidance-si","article_id":"2611483678","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/a-look-at-ssy-groups-valuation-after-2025-profit-guidance-si","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611483678","pubTimestamp":1771244416,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSY Group (SEHK:2005) has issued preliminary 2025 earnings guidance, telling investors to expect a 45% to 60% reduction in profit attributable to equity shareholders compared with the HK$1,061,150,000 reported for 2024.\nSee our latest analysis for SSY Group.\nAt a share price of HK$3.02, SSY Group has a modest 1-day share price return of a 0.33% decline, while its year-to-date share price return of 5.59% contrasts with a 3-year total shareholder return of a 28.75% decline. This suggests that...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SSY":"Sunlink Health Systems Inc"},"translate_title":"2025年利润指引表明盈利大幅下降后SSY集团的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SSY":1.5},"content_text":"SSY Group (SEHK:2005) has issued preliminary 2025 earnings guidance, telling investors to expect a 45% to 60% reduction in profit attributable to equity shareholders compared with the HK$1,061,150,000 reported for 2024. See our latest analysis for SSY Group. At a share price of HK$3.02, SSY Group has a modest 1-day share price return of a 0.33% decline, while its year-to-date share price return of 5.59% contrasts with a 3-year total shareholder return of a 28.75% decline. This suggests that recent momentum is firmer than the longer-term experience as investors react to the latest earnings guidance and earlier product approvals. If this guidance shift has you reassessing where you want exposure, it could be a good moment to broaden your search and check out 103 top founder-led companies as potential alternatives. With 2025 profits expected to fall sharply and the share price still above its recent lows, the real question is whether SSY Group is now quietly cheap, or if the market is already accounting for weaker earnings ahead. AdvertisementPrice to earnings of 13.3x: is it justified? SSY Group is flagged as good value on a P/E of 13.3x, with the shares at HK$3.02 and screens suggesting the valuation sits below both peers and fair value estimates. The P/E ratio compares the current share price to earnings per share. It effectively shows how much investors are paying for each unit of current profit. For a pharmaceutical manufacturer like SSY Group, this often reflects how confident the market is in the stability of its earnings base and the prospects of its product portfolio. Here, SSY Group is described as good value against both the Hong Kong pharmaceuticals industry average, also at 13.3x, and a peer average of 26.2x, which points to a clear valuation gap. It is also assessed as attractive versus an estimated fair P/E of 15.9x, a level the market could conceivably move towards if sentiment and earnings hold up against the weaker 2025 guidance already flagged. Explore the SWS fair ratio for SSY Group Result: Price to earnings of 13.3x (UNDERVALUED) However, you are still relying on guidance that points to a sharp 2025 profit drop, along with a multiyear total shareholder return that has been negative. Find out about the key risks to this SSY Group narrative. Another view using our DCF model The P/E of 13.3x suggests SSY Group looks inexpensive, but our DCF model points to something stronger, with the shares at HK$3.02 compared with an estimated future cash flow value of HK$6.62. If both views are right, it raises the question of whether the market is being overly cautious about the 2025 guidance shock. Look into how the SWS DCF model arrives at its fair value. 2005 Discounted Cash Flow as at Feb 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out SSY Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 224 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own SSY Group Narrative If you see the numbers differently or prefer to shape your own view from the ground up, you can build a personal thesis in just a few minutes, starting with Do it your way. A great starting point for your SSY Group research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? If you are weighing what to do next after reviewing SSY Group, do not stop here. Widen your research now so you are not reacting late.  Spot potential value early by checking our list of screener containing 575 high quality undiscovered gems that combine strong fundamentals with less market attention. Strengthen your core holdings with companies filtered through our solid balance sheet and fundamentals stocks screener (371 results) focused on financial resilience. Balance risk and reward by reviewing 325 resilient stocks with low risk scores so you are not missing companies that score well on our risk checks.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611483678","isCrawlerRequest":true}